Proxy Results, Amendments to Bylaws, Management Change/Compensation (Form 8-K)

As reported below under Item 5.07 of this Current Report, BioSig Technologies, Inc. (the "Company"), held its a special meeting of stockholders on September 5, 2025 (the "Special Meeting"), at which the Company's stockholders approved the Third Amendment (the "Incentive Plan Amendment") to the Company's 2023 Long-Term Incentive Plan, as amended (the "Incentive Plan"), to increase the total number of shares of common stock, par value $0.001 per share, authorized for issuance under the Incentive Plan by 10,359,211, to a total of 14,735,806 shares.

For more information about the Incentive Plan Amendment, see the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on August 4, 2025, as amended on August 15, 2025, September 2, 2025 and September 3, 2025 (the "Proxy Statement"), the relevant portions of which are incorporated herein by reference. The foregoing description of the Incentive Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Incentive Plan Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report and is incorporated by reference herein.

As described in Item 5.07 below, the stockholders of the Company voted to, among other things, approve the Company's Ninth Amendment to the Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company's common stock from 200,000,000 to 500,000,000 (the "Ninth Certificate of Amendment"). The additional common stock authorized by the Ninth Certificate of Amendment has rights identical to the Company's currently outstanding common stock. The Company filed the Ninth Certificate of Amendment, which was effective upon filing, with the Secretary of State of the State of Delaware on September 5, 2025.

The foregoing description of the Ninth Certificate of Amendment does not purport to be complete and is subject to, and is qualified in its entirety by reference to, the full text of the Ninth Certificate of Amendment, which is attached as Exhibit 3.1 to this Current Report on Form 8-K.

As of the record date of July 30, 2025, holders of record of the Company's common stock were entitled to one vote per share, totaling 31,326,659 votes, and certain holders of record of the Company's Series C Convertible Preferred Stock, subject to the beneficial ownership limitation pursuant to the terms of such preferred stock as set forth in the certificate of designation for such preferred stock, were entitled to an aggregate of 354,818 votes.

At the Company's Special Meeting, the Company's stockholders voted on Proposal 2, Proposal 3, Proposal 4, Proposal 5 and Proposal 6, each as set forth below. For more information about the foregoing proposals, see the Proxy Statement. The Special Meeting was then adjourned, pending Nasdaq approval, on Proposal 1, the proposal to approve the issuance of approximately 109,070,079 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), subject to certain adjustments, and one share of the Company's Super Voting Preferred Stock, pursuant to the Share Purchase Agreement, as amended, by and among the Company, certain subsidiaries of the Company named therein, and Streamex Exchange Corporation ("Streamex"), in connection with the Company's consummated acquisition of Streamex, each as described further in the Proxy Statement.

The Special Meeting will resume with respect to Proposal 1 on September 26, 2025 at 10am Eastern Time. The reconvened meeting will be held virtually at www.virtualshareholdermeeting.com/BSGM2025SM. The record date for determining stockholders eligible to vote at the Special Meeting remains the same, July 30, 2025.

The final results for Proposal 2, Proposal 3, Proposal 4, Proposal 5 and Proposal 6, each as set forth in the Proxy Statement, are as follows:

No other matters were considered or voted upon at the Special Meeting.